List of works - Brent A Appleton

2-Amino-7-substituted benzoxazole analogs as potent RSK2 inhibitors

scientific article

A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients

scientific article

A specificity map for the PDZ domain family

scientific article

A structural portrait of the PDZ domain family

scientific article

Convergent and divergent ligand specificity among PDZ domains of the LAP and zonula occludens (ZO) families.

scientific article

Crystal structure of the cytomegalovirus DNA polymerase subunit UL44 in complex with the C terminus from the catalytic subunit. Differences in structure and function relative to unliganded UL44

scientific article published on 20 December 2005

Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.

scientific article published on 30 May 2017

Design and synthesis of potent RSK inhibitors

scientific article published on 21 August 2018

Discovery and Optimization of Phosphopantetheine Adenylyltransferase Inhibitors with Gram-Negative Antibacterial Activity

scientific article published on 13 April 2018

Discovery of Potent and Selective RSK Inhibitors as Biological Probes

scientific article

Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma

scientific article published on 3 August 2015

Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design.

scientific article

Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1

scientific article

Fragment-Based Drug Discovery of Inhibitors of Phosphopantetheine Adenylyltransferase from Gram-Negative Bacteria.

scientific article published on 2 March 2018

Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitors.

scientific article

Inhibition of Wnt signaling by Dishevelled PDZ peptides

scientific article

Mathematical and Structural Characterization of Strong Nonadditive Structure-Activity Relationship Caused by Protein Conformational Changes

scientific article published on 20 August 2018

Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers

scientific article

Residues of human cytomegalovirus DNA polymerase catalytic subunit UL54 that are necessary and sufficient for interaction with the accessory protein UL44

scientific article published on January 2004

Specific residues in the connector loop of the human cytomegalovirus DNA polymerase accessory protein UL44 are crucial for interaction with the UL54 catalytic subunit.

scientific article

Structural and functional analysis of the PDZ domains of human HtrA1 and HtrA3

scientific article

Structural and functional analysis of the ligand specificity of the HtrA2/Omi PDZ domain

scientific article

Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding

scientific article

The cytomegalovirus DNA polymerase subunit UL44 forms a C clamp-shaped dimer.

scientific article

Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site

scientific article

List of works by Brent A Appleton

2-Amino-7-substituted benzoxazole analogs as potent RSK2 inhibitors

A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients

A specificity map for the PDZ domain family

A structural portrait of the PDZ domain family

Convergent and divergent ligand specificity among PDZ domains of the LAP and zonula occludens (ZO) families.

Crystal structure of the cytomegalovirus DNA polymerase subunit UL44 in complex with the C terminus from the catalytic subunit. Differences in structure and function relative to unliganded UL44

Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.

Design and synthesis of potent RSK inhibitors

Discovery and Optimization of Phosphopantetheine Adenylyltransferase Inhibitors with Gram-Negative Antibacterial Activity

Discovery of Potent and Selective RSK Inhibitors as Biological Probes

Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma

Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design.

Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1

Fragment-Based Drug Discovery of Inhibitors of Phosphopantetheine Adenylyltransferase from Gram-Negative Bacteria.

Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitors.

Inhibition of Wnt signaling by Dishevelled PDZ peptides

Mathematical and Structural Characterization of Strong Nonadditive Structure-Activity Relationship Caused by Protein Conformational Changes

Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers

Residues of human cytomegalovirus DNA polymerase catalytic subunit UL54 that are necessary and sufficient for interaction with the accessory protein UL44

Specific residues in the connector loop of the human cytomegalovirus DNA polymerase accessory protein UL44 are crucial for interaction with the UL54 catalytic subunit.

Structural and functional analysis of the PDZ domains of human HtrA1 and HtrA3

Structural and functional analysis of the ligand specificity of the HtrA2/Omi PDZ domain

Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding

The cytomegalovirus DNA polymerase subunit UL44 forms a C clamp-shaped dimer.

Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site